Filgotinib Maleate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Filgotinib Maleate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
82
Registered trials
162
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Filgotinib Maleate can convert its Small molecule drug profile and JAK1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Filgotinib Maleate (query alias: filgotinib) |
|---|---|
| Modality / target | Small molecule drug; JAK1; JAK1 inhibitors |
| Highest global status | Approved |
| Originator | Lakefront Biotherapeutics |
| Active developers | Gilead Sciences, Inc., Alfasigma SpA, Gilead Sciences Ireland UC |
The MCP disease footprint includes Colitis, Ulcerative, Rheumatoid Arthritis, Ulcerative colitis, active moderate. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07576452 | Phase 4 | Not yet recruiting | 240 | Clinical remission |
| NCT06964113 | Phase 4 | Active, not recruiting | 94 | Percentage of Participants Achieving Clinical Remission at Week 10 or 22 |
| NCT07553182 | Phase 3 | Recruiting | 80 | Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation at each visit throughout the duration of the study. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
SAFETY AND TREATMENT PERSISTENCE OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE MULTICENTRE SOFIA STUDY (OBSERVATIONAL STUDY ON THE SAFETY OF FILGOTINIB IN RHEUMATOID ARTHRITIS)
Not Applicable; n=254; evaluation: Positive. Reported fields: AE = 153.0 Event
IMPACT OF FILGOTINIB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINT OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE 3 OLINGUITO TRIAL
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: SPARCC inflammation score of the SIJ(16-week): P-Value = <0.001; SPARCC inflammation score of the SIJ(16-week): P-Value = <0.001
EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS OF THE FINCH 4 LONG-TERM EXTENSION STUDY
Phase 3; n=3452; evaluation: Positive. Reported fields: -; CDAI remission(NRI analysis) = 11.1 % ; CDAI remission(NRI analysis) = 11.1 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Filgotinib Maleate addresses Colitis, Ulcerative, Rheumatoid Arthritis, Ulcerative colitis, active moderate. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-10-30 | Galapagos completes transaction to transfer Jyseleca® business to Alfasigma | Approved | US$54.8M upfront; US$131.5M milestones |
| 2019-12-23 | Gilead And Eisai Enter Into Agreement In Japan For The Co-Promotion Of The Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval | NDA/BLA | Financial terms not disclosed |
| 2015-12-17 | Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases | Phase 2 | US$725.0M upfront; US$1,350.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Biomarkers for determining treatment of ulcerative colitis with filgotinib”. The milestone feed surfaced a patent-application signal described as “Biomarkers for determining treatment of ulcerative colitis with filgotinib”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
